Obesity Rates in the U.S. Climbed to About 40% of Adults and 20% of Youth in 2023

A new study in Circulation finds U.S. adult obesity rose from 30% (1999) to 41% (2023), with severe obesity increasing from 5% to 10% and abdominal obesity from 48% to 61%. For youth, obesity grew about 30% over the period, severe obesity rose ~50%, and abdominal obesity roughly tripled. The article emphasizes ongoing BMI/waist monitoring and highlights treatment options such as GLP-1 receptor agonists and bariatric surgery, implying growing demand for obesity-related therapies amid rising cardiometabolic risk.

Analysis

This is not a clean short-horizon equity catalyst; it is a multi-year demand confirmation for obesity treatment and downstream chronic-care utilization. The important mechanism is not the prevalence print itself, but the shift from obesity being a lifestyle issue to a routinized, screenable condition that can drive more PCP visits, more diagnosis coding, and better reimbursement justification for GLP-1s, bariatric procedures, and cardiometabolic monitoring. That favors the obesity-treatment stack more than the broad consumer complex.

For the named names, LTH is the only one with a plausible second-order tailwind: a higher-health-attention environment can support fitness membership demand and ancillary services, but that effect is slow and easily swamped by discretionary pressure. GAP and TGT are not direct losers from the epidemiology; any read-through would be via long-cycle assortment and sizing mix, not next-quarter revenue. If anything, the more actionable retail implication is that the market may eventually reward brands with better inclusive sizing and higher-margin health/wellness adjacency, but that is a 6-18 month product-cycle story, not a trade on this release.

Contrarian view: consensus will over-interpret the prevalence data as bullish for GLP-1s, but the market already knows obesity is sticky. The real catalysts are payer expansion, supply normalization, adherence/refill persistence, and whether waist-circumference-based screening becomes a billing standard. If those do not improve, the epidemiology remains background noise and the trade fades.

Key Decisions for Investors

• No immediate trade in GAP or TGT on this release; wait for company-specific evidence of sizing mix, returns, or traffic changes before treating obesity trends as earnings-relevant.
• Use any pullback to build a 3-6 month long bias in obesity-treatment leaders such as LLY/NVO; the thesis is secular utilization growth, but the trade fails if payer restrictions tighten or gross-to-net expands faster than volume.
• Modest tactical long LTH on weakness as a slow-burn wellness proxy, with the understanding that this is a low-beta, sentiment-driven trade rather than a direct fundamental catalyst.
• Set an alert for CMS/commercial coverage changes, refill persistence data, and GLP-1 supply commentary; those are the actual inflection points that would make the obesity trend tradable.
• If you want relative value, consider a small LTH-over-TGT expression only after management commentary confirms consumer wellness engagement; otherwise keep it on the watchlist rather than forcing a position.